RxDoctor Payments Data

Eliseo Colon-Carreras, MD

Pulmonary Disease · Lexington, KYNPI 1982606422

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (48.0%), education and travel and lodging — rather than concentrated in one kind of arrangement. 48 manufacturers reported payments, led by Intuitive Surgical at 46.0% of the total. 2025 is the largest year on record at $11,140, 5.2 times the $2,155 reported in 2019.

$17,048in general payments, 2019–2025

Across 335 payments — averaging $50.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$8K
  • Pulmonx Corporation$2K
  • Boehringer Ingelheim$1K
  • GSK$1K
  • Sanofi$511
  • Johnson & Johnson$458
  • plus $4K from 42 others

What the payments were for

  • Travel & lodging$1,71210%
  • Food & beverage$8,18848%
  • Education$7,14742%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,048 in reported general payments places this provider in the 85th percentile of 226 pulmonary disease providers in Kentucky.

See all pulmonary disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$113,260
Medicare patients
300
Services billed
941

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate15$196,237
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$33,737
Breztri AerosphereBudesonide/Glycopyr/Formoterol42$32,908
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$9,628
Albuterol Sulfate HfaAlbuterol Sulfate47$1,458
Ventolin HfaAlbuterol Sulfate11$734
Doxycycline Hyclate23$120
Prednisone74$92
Azithromycin30$64
Levofloxacin13$33

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev$1,245$196,23715 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,010$43,36552 claims
AstraZenecaBreztri Aerosphere$247$32,90842 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 226 pulmonary disease providers in Kentucky.

Other pulmonary disease in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →